BMS's Sprycel gets FDA priority review for newly diagnosed CML
This article was originally published in Scrip
The supplemental NDA for Bristol-Myers Squibb/Otsuka Pharmaceutical's second generation BCR-ABL inhibitor Sprycel (dasatinib) for the treatment of newly diagnosed, chronic-phase chronic myeloid leukaemia (CML) has been accepted for filing by the US FDA and been granted a priority review designation.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.